After grabbing 24340.0 shares, the institutional investor is now in possession of 24340.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.74% having worth around $63527.0. Moreover, Citadel Securities LLC increased its share by 20428.0 to have a control over 20428.0 shares. And The Vanguard Group, Inc. raised its holdings to 1795.0 shares by acquiring 12232.0 shares or 0.37% of the stake.
Hoth Therapeutics Inc. (HOTH) concluded trading on 09/13/23 at a closing price of $1.92, with 7.66 million shares of worth about $14.71 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -22.58% during that period and on Wednesday the price saw a loss of about -28.36%. Currently the company’s common shares owned by public are about 3.30M shares, out of which, 3.26M shares are available for trading.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 2 analysts are covering the HOTH stock and their offered price forecasts bring an average price target of $7.50. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $12.00 and could fall to a lowest price of $3.00. The stock’s current price level is 79.79% above of average price target set by the analysts, while a rise to estimated low would result in gain of 36.0% for the stock. However, touching the estimated high of $12.00 would mean a gain of 84.0% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 3 times over the past 12 months. They bought 25,075 shares in 3 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Vanguard Extended Market Index Fu, Fidelity Extended Market Index Fu, and Fidelity Nasdaq Composite Index F are the top 3 mutual funds which are holding stakes in Hoth Therapeutics Inc. Vanguard Extended Market Index Fu is currently holding 22535.0 shares of worth totaling $58816.0. The company recently came buying 10303.0 shares which brought its stake up to 0.68% of the company’s outstanding shares. Fidelity Nasdaq Composite Index F, after buying 1988.0 shares, have now control over 0.06% of the stake in the company. It holds 0.0 shares of worth $5189.0.
Hoth Therapeutics Inc. (NASDAQ: HOTH) started trading at $3.11, above $0.43 from concluding price of the previous day. Stock saw a price change of -16.16% in past 5 days and over the past one month there was a price change of -25.00%. Year-to-date (YTD), HOTH shares are showing a performance of -75.38% which decreased to -81.27% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.52 but also hit the highest price of $12.50 during that period. The average intraday trading volume for Hoth Therapeutics Inc. shares is 113.09K. The stock is currently trading -18.50% below its 20-day simple moving average (SMA20), while that difference is down -24.64% for SMA50 and it goes to -36.09% lower than SMA200.
Geode Capital Management LLC acquired 24340.0 shares of Hoth Therapeutics Inc. having value of about $63527.0. Hoth Therapeutics Inc. (NASDAQ: HOTH) currently have 3.30M outstanding shares and institutions hold larger chunk of about 8.30% of that. Holding of mutual funds in the company is about 1.20% while other institutional holders and individual stake holders have control over 1.41% and 0.76% of the stake respectively.
The stock has a current market capitalization of $5.93M and its 3Y-monthly beta is at 0.42. It has posted earnings per share of -$6.18 in the same period. It has Quick Ratio of 6.90 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HOTH, volatility over the week remained 29.78% while standing at 11.24% over the month.
Analysts are in expectations that Hoth Therapeutics Inc. (HOTH) stock would likely to be making an EPS of -$0.83 in the current quarter, while forecast for next quarter EPS is -$0.8 and it is -$1.45 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.88 which is -$0.79 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$2.05 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 40.70% while it is estimated to increase by 68.70% in next year.
Analysts at 2 brokerage firms have issued recommendations for the Hoth Therapeutics Inc. (HOTH)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.00. Out of those 2 Wall Street analysts, 2 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by The Benchmark Company on October 15, 2019 offering a Speculative buy rating for the stock and assigned a target price of $10 to it.
